Original Article

You have full text access to this OnlineOpen article

Randomized trial of intensive bisphosphonate treatment versus symptomatic management in paget's disease of bone

  1. Anne L Langston1,2,
  2. Marion K Campbell3,
  3. William D Fraser4,
  4. Graeme S MacLennan3,
  5. Peter L Selby5,
  6. Stuart H Ralston1,2,*

Article first published online: 18 DEC 2009

DOI: 10.1359/jbmr.090709

Issue

Journal of Bone and Mineral Research

Journal of Bone and Mineral Research

Volume 25, Issue 1, pages 20–31, January 2010

Additional Information

How to Cite

Langston, A. L., Campbell, M. K., Fraser, W. D., MacLennan, G. S., Selby, P. L. and Ralston, S. H. (2010), Randomized trial of intensive bisphosphonate treatment versus symptomatic management in paget's disease of bone. J Bone Miner Res, 25: 20–31. doi: 10.1359/jbmr.090709

Author Information

  1. 1

    Rheumatic Diseases Unit, Institute of Genetics and Molecular Medicine University of Edinburgh, United Kingdom

  2. 2

    Edinburgh Clinical Trials Unit, University of Edinburgh, United Kingdom

  3. 3

    Health Services Research Unit, University of Aberdeen, United Kingdom

  4. 4

    Department of Clinical Biochemistry, University of Liverpool, United Kingdom

  5. 5

    Department of Medicine, University of Manchester, United Kingdom

*Molecular Medicine Centre, Western General Hospital, Edinburgh EH2 SX4, United Kingdom.

Publication History

  1. Issue published online: 20 JAN 2010
  2. Article first published online: 18 DEC 2009
  3. Manuscript Accepted: 1 JUL 2009
  4. Manuscript Revised: 10 APR 2009
  5. Manuscript Received: 11 SEP 2008

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (174K)

References

  • 1
    Ralston SH, Langston AL, Reid IR. Pathogenesis and management of Paget's disease of bone. Lancet. 2008; 372: 155–163.
  • 2
    van Staa TP, Selby P, Leufkens HG, Lyles K, Sprafka JM, Cooper C. Incidence and natural history of Paget's disease of bone in England and Wales. J Bone Miner Res. 2002; 17: 465–471.
    Direct Link:
  • 3
    Gold DT, Boisture J, Shipp KM, Pieper CF, Lyles KW. Paget's disease of bone and quality of life. J Bone Miner Res. 1996; 11: 1897–1904.
  • 4
    Langston AL, Campbell MK, Fraser WD, Maclennan G, Selby P, Ralston SH. Clinical determinants of quality of life in Paget's disease of bone. Calcif Tissue Int. 2007; 80: 1–9.
  • 5
    Miller PD, Brown JP, Siris ES, Hoseyni MS, Axelrod DW, Bekker PJ. A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget's disease of bone. Paget's Risedronate/Etidronate Study Group. Am J Med. 1999; 106: 513–520.
  • 6
    Siris ES, Weinstein RS, Altman R, et al. Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone. J Clin Endocrinol Metab. 1996; 81: 961–967.
  • 7
    Lyles KW, Siris ES, Singer FR, Meunier PJ. A clinical approach to diagnosis and management of Paget's disease of bone. J Bone Miner Res. 2001; 16: 1379–1387.
    Direct Link:
  • 8
    Siris ES. Goals of treatment for Paget's disease of bone. J Bone Miner Res. 1999; 14: S49–52.
  • 9
    Reid IR, Miller P, Lyles K, et al. Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. N Engl J Med. 2005; 353: 898–908.
  • 10
    Altman RD, Johnston CC, Khairi MR, Wellman H, Serafini AN, Sankey RR. Influence of disodium etidronate on clinical and laboratory manifestations of Paget's disease of bone (osteitis deformans). N Engl J Med. 1973; 289: 1379–1384.
  • 11
    Ralston SH, Boyce BF, Cowan RA, et al. The effect of 1,α-hydroxyvitamin D3 on the mineralization defect in disodium etidronate treated Paget's disease: a double-blind, randomized study. J Bone Miner Res. 1987; 2: 5–12.
    Direct Link:
  • 12
    Reid IR, Nicholson GC, Weinstein RS, et al. Biochemical and radiologic improvement in Paget's disease of bone treated with alendronate: a randomized, placebo-controlled trial. Am J Med. 1996; 101: 341–348.
  • 13
    Roland M, Torgerson DJ. What are pragmatic trials? Br Med J. 1998; 316: 285.
  • 14
    Fraser WD, Stamp TC, Creek RA, Sawyer JP, Picot C. A double-blind, multicenter, placebo-controlled study of tiludronate in Paget's disease of bone. Postgrad Med J. 1997; 73: 496–502.
  • 15
    Khairi MR, Johnston CC Jr, Altman RD, Wellman HN, Serafini AN, Sankey RR. Treatment of Paget disease of bone (osteitis deformans): results of a one-year study with sodium etidronate. JAMA. 1974; 230: 562–567.
  • 16
    Cranney A, Guyatt G, Griffith L, Wells G, Tugwell P, Rosen C. Meta-analyses of therapies for postmenopausal osteoporosis: IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev. 2002; 23: 570–578.
  • 17
    Selby PL, Davie MW, Ralston SH, Stone MD. Guidelines on the management of Paget's disease of bone. Bone. 2002; 31: 366–373.
  • 18
    Altman DG, Bland JM. Treatment allocation by minimisation. Br Med J. 2005; 330: 843.
  • 19
    Singer FR, Clemens TL, Eusebio RA, Bekker PJ. Risedronate, a highly effective oral agent in the treatment of severe Paget's disease. J Clin Endocrinol Metab. 1998; 83: 1906–1910.
  • 20
    Ziebland S, Fitzpatrick R, Jenkinson C, Mowat A, Mowat A. Comparison of two approaches to measuring change in health status in rheumatoid arthritis: the Health Assessment Questionnaire (HAQ) and modified HAQ. Ann Rheum Dis. 1992; 51: 1202–1205.
  • 21
    Ware JE Jr, Gandek B. Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) Project. J Clin Epidemiol. 1998; 51: 903–912.
  • 22
    Ware JEJ, Keller SD, Hatoum HT, Kong SX. The SF-36 Arthritis-Specific Health Index (ASHI): I. Development and cross-validation of scoring algorithms. Med Care. 1999; 37: MS40–50.
  • 23
    Melton LJ III, Tiegs RD, Atkinson EJ, O'Fallon WM. Fracture risk among patients with Paget's disease: a population-based cohort study. J Bone Miner Res. 2000; 15: 2123–2128.
    Direct Link:
  • 24
    Kanis JA. Pathophysiology and Treatment of Paget's Disease of Bone. 2nd Ed, 1998, Dunitz, London.
  • 25
    Roux C, Gennari C, Farrerons J, et al. Comparative prospective, double-blind, multicenter study of the efficacy of tiludronate and etidronate in the treatment of Paget's disease of bone. Arthritis Rheum. 1995; 38: 851–858.
    Direct Link:
  • 26
    Siris ES, Feldman F. Natural history of untreated Paget's disease of the tibia. J Bone Miner Res. 1997; 12: 691–692.
    Direct Link:
  • 27
    Ravault A, Meunier PJ. [Long-term follow-up of 88 patients with Paget's disease treated by discontinuous courses of low-dose disodium etidronate]. Rev Rhum Mal Osteoartic. 1989; 56: 293–302 [in French].
  • 28
    Siris ES, Chines AA, Altman RD, et al. Risedronate in the treatment of Paget's disease of bone: an open label multicenter study. J Bone Miner Res. 1998; 13: 1032–1038.
    Direct Link:
  • 29
    Arden-Cordone M, Siris ES, Lyles KW, et al. Antiresorptive effect of a single infusion of microgram quantities of zoledronate in Paget's disease of bone. Calcif Tissue Int. 1997; 60: 415–418.
  • 30
    Siris ES. A potent new bisphosphonate for Paget's disease of bone. Am J Med. 1996; 101: 339–340.
  • 31
    Wysowski DK, Chang JT. Alendronate and risedronate: reports of severe bone, joint, and muscle pain. Arch Intern Med. 2005; 165: 346–347.
  • 32
    Bock O, Boerst H, Thomasius FE, et al. Common musculoskeletal adverse effects of oral treatment with once weekly alendronate and risedronate in patients with osteoporosis and ways for their prevention. J Musculoskel Neuronal Interact. 2007; 7: 144–148.
  • 33
    Hosking D, Lyles K, Brown JP, et al. Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate. J Bone Miner Res. 2007; 22: 142–148.
    Direct Link:
  • 34
    Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med. 2006; 144: 753–761.
  • 35
    Cummings SR, Schwartz AV, Black DM. Alendronate and atrial fibrillation. N Engl J Med. 2007; 356: 1895–1896.
  • 36
    Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007; 356: 1809–1822.
  • 37
    Schneider JP. Bisphosphonates and low-impact femoral fractures: current evidence on alendronate-fracture risk. Geriatrics. 2009; 64: 18–23.
View Full Article (HTML) Get PDF (174K)